Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase EARLY_PHASE1 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 7Thoracic 3Other hematologic neoplasm 3Head & Neck 3Gastrointestinal 3Lymphoid 2CNS 2Breast 2NET 1Endocrine 1Dermatologic 1

Conditions

Rectal Neoplasms 1Pancreatic Neuroendocrine Tumors (pNET) 1Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

Fluorouracil 56Specimen Handling 51Oxaliplatin 49Leucovorin 46Magnetic Resonance Spectroscopy 45Bevacizumab 43Gemcitabine 39Irinotecan 30Cetuximab 27Nivolumab 25130-nm albumin-bound paclitaxel 25Cisplatin 24Biopsy 24pembrolizumab 22Paclitaxel 22Capecitabine 19atezolizumab 18durvalumab 14Taxes 14Folfox protocol 14Carboplatin 13X-Rays 12Radiotherapy 12Cyclophosphamide 12fludarabine 11dehydroftorafur 10Radiation 10Albumin-Bound Paclitaxel 10Surgical Procedures, Operative 9Immunoglobulin G 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Watchful Waiting × Gastrointestinal × 30 days × Clear all
NCT03233711 2026-05-29

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
344 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT03594630 2026-05-20

Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Recruiting
120 enrolled
Gastrointestinal

Rectal Neoplasms

NCT07591493 2026-05-15

ADJUPANET

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Not yet recruiting
300 enrolled
EndocrineGastrointestinalNET

Pancreatic Neuroendocrine Tumors (pNET)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡